Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C

Explore clinical trials studying Hepatitis C. Study availability and eligibility vary by location and protocol.

1,296 public trials 40 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C trial results

Completed

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02349048

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +13 more
Locations
  • Bakersfield, California, United States
  • Jacksonville, Florida, United States
  • Lutherville, Maryland, United States
  • Winston-Salem, North Carolina, United States
View Trial Details
Completed

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

NCT01628692

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • San Francisco General Hospital San Francisco, California, United States
  • Kaiser Permanente Med Ctr San Francisco, California, United States
  • Indiana University Indianapolis, Indiana, United States
  • Johns Hopkins University Lutherville, Maryland, United States
View all 26 locations
View Trial Details
Completed

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

NCT02032875

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • University Of Miami Schiff Center For Liver Diseases Miami, Florida, United States
  • University Of Michigan Health System Ann Arbor, Michigan, United States
  • Baylor St. Luke'S Medical Center Houston, Texas, United States
  • American Research Corporation San Antonio, Texas, United States
View Trial Details
Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

NCT02319031

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Local Institution Darlinghurst, New South Wales, Australia
  • Local Institution Greenslopes, Queensland, Australia
  • Local Institution Adelaide, South Australia, Australia
  • Local Institution Clayton, Victoria, Australia
View Trial Details

Related conditions